SG10201913428QA - Humanized rodents that express heavy chains containing vl domains - Google Patents

Humanized rodents that express heavy chains containing vl domains

Info

Publication number
SG10201913428QA
SG10201913428QA SG10201913428QA SG10201913428QA SG10201913428QA SG 10201913428Q A SG10201913428Q A SG 10201913428QA SG 10201913428Q A SG10201913428Q A SG 10201913428QA SG 10201913428Q A SG10201913428Q A SG 10201913428QA SG 10201913428Q A SG10201913428Q A SG 10201913428QA
Authority
SG
Singapore
Prior art keywords
domains
heavy chains
chains containing
express heavy
humanized rodents
Prior art date
Application number
SG10201913428QA
Inventor
Lynn Macdonald
Cagan Gurer
Karolina Meagher
Sean Stevens
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201913428QA publication Critical patent/SG10201913428QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Housing For Livestock And Birds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201913428QA 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains SG10201913428QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31

Publications (1)

Publication Number Publication Date
SG10201913428QA true SG10201913428QA (en) 2020-03-30

Family

ID=47714588

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201404477YA SG11201404477YA (en) 2012-02-01 2013-02-01 HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS
SG10201913428QA SG10201913428QA (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
SG10201606256TA SG10201606256TA (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201404477YA SG11201404477YA (en) 2012-02-01 2013-02-01 HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201606256TA SG10201606256TA (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Country Status (26)

Country Link
US (3) US20130212719A1 (en)
EP (3) EP3597038B1 (en)
JP (6) JP2015505477A (en)
KR (2) KR20190006029A (en)
CN (2) CN104202971B (en)
AU (3) AU2013204758B2 (en)
BR (1) BR112014018843B1 (en)
CA (1) CA2863175A1 (en)
CY (2) CY1122419T1 (en)
DK (2) DK2809150T3 (en)
ES (2) ES2753774T3 (en)
HK (1) HK1202771A1 (en)
HR (2) HRP20192218T1 (en)
HU (2) HUE046744T2 (en)
IL (3) IL233827A0 (en)
LT (2) LT3597038T (en)
ME (1) ME03611B (en)
MX (2) MX2020003491A (en)
NZ (3) NZ719228A (en)
PL (2) PL2809150T3 (en)
PT (2) PT2809150T (en)
RS (2) RS59699B1 (en)
RU (2) RU2770016C2 (en)
SG (3) SG11201404477YA (en)
SI (2) SI2809150T1 (en)
WO (1) WO2013116609A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
JP5944312B2 (en) 2009-07-08 2016-07-05 カイマブ・リミテッド Animal models and therapeutic molecules
EP3960865A1 (en) * 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
EP2739740B1 (en) 2011-08-05 2019-10-02 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
EP4091442A1 (en) 2011-09-19 2022-11-23 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
KR102038974B1 (en) 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 Humanized light chain mice
KR20190006029A (en) * 2012-02-01 2019-01-16 리제너론 파마슈티칼스 인코포레이티드 Humanized rodents that express heavy chains containing vl domains
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
KR102126217B1 (en) 2012-06-12 2020-06-24 리제너론 파마슈티칼스 인코포레이티드 Humanized non-human animals with restricted immunoglobulin heavy chain loci
TR201810255T4 (en) 2013-02-20 2018-08-27 Regeneron Pharma Non-human animals having modified immunoglobulin heavy chain sequences.
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
JP7133902B2 (en) 2013-10-01 2022-09-09 カイマブ・リミテッド Animal models and therapeutic molecules
BR112016021679A2 (en) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. antigen binding protein, methods of producing an antigen binding protein and identifying one or more antigen binding proteins, hybridoma, nucleic acid, cell, and genetically modified non-human animal.
EP3119194B1 (en) 2014-03-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
AU2016232715A1 (en) * 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US20180094243A1 (en) * 2015-04-03 2018-04-05 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
EP3457840B1 (en) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
CN110719732B (en) * 2017-03-30 2022-11-18 犹他州立大学 Transgenic silkworms expressing spider silk
CA3084049A1 (en) * 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
SG11202008799PA (en) * 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CN112312766A (en) * 2018-06-14 2021-02-02 瑞泽恩制药公司 Non-human animals having DH-DH rearrangement capability in immunoglobulin heavy chain coding sequences
WO2022056276A1 (en) 2020-09-11 2022-03-17 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
KR20230147048A (en) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 Mice expressing humanized Fc alpha receptors
CN114645042A (en) * 2020-12-18 2022-06-21 中国食品药品检定研究院 Method for constructing transgenic mouse with recombinant macrophage for expressing luciferase and red fluorescent protein
CN114196626A (en) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 Umbilical cord mesenchymal stem cells and isolated culture and amplification method thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
IL154751A0 (en) * 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (en) * 2000-11-17 2007-08-15 罗切斯特大学 In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
AU2003230741A1 (en) * 2002-03-22 2003-10-13 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
CA2532117C (en) * 2003-07-15 2012-07-10 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
PT2767161T (en) 2004-10-19 2018-04-20 Regeneron Pharma Method for generating an non-human animal homozygous for a genetic modification
CA2584814A1 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in non-human transgenic animals
AU2007235496B2 (en) * 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PL2064325T3 (en) * 2006-09-01 2012-05-31 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
CN101970491A (en) * 2007-08-30 2011-02-09 沃尔特及伊莱萨霍尔医学研究院 Dendritic cell marker and uses thereof
AR068563A1 (en) * 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd CONSTANT MUTANT ANTIBODY REGION
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
RU2731084C2 (en) * 2008-06-27 2020-08-28 Мерюс Н.В. Producing non-human mammalian antibodies
US20100069262A1 (en) * 2008-08-29 2010-03-18 Symphogen A/S Method for Cloning Avian-Derived Antibodies
WO2010091182A2 (en) * 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
JP5944312B2 (en) * 2009-07-08 2016-07-05 カイマブ・リミテッド Animal models and therapeutic molecules
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (en) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
CN103228130B (en) * 2010-06-17 2016-03-16 科马布有限公司 Animal model and treatment molecule
EP3960865A1 (en) * 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
ME03732B (en) * 2011-02-25 2021-01-20 Regeneron Pharma ADAM6 mice
EP2739740B1 (en) * 2011-08-05 2019-10-02 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
KR102038974B1 (en) * 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 Humanized light chain mice
KR20190006029A (en) * 2012-02-01 2019-01-16 리제너론 파마슈티칼스 인코포레이티드 Humanized rodents that express heavy chains containing vl domains
KR102126217B1 (en) * 2012-06-12 2020-06-24 리제너론 파마슈티칼스 인코포레이티드 Humanized non-human animals with restricted immunoglobulin heavy chain loci
RS60886B1 (en) * 2016-11-04 2020-11-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus

Also Published As

Publication number Publication date
US20170094955A1 (en) 2017-04-06
IL268675A (en) 2019-10-31
RU2664185C2 (en) 2018-08-15
BR112014018843A2 (en) 2017-07-04
HRP20192218T1 (en) 2020-03-06
SI2809150T1 (en) 2019-11-29
CN106117364B (en) 2021-08-31
JP2018075041A (en) 2018-05-17
CN106117364A (en) 2016-11-16
RU2014133653A (en) 2016-03-20
EP2809150A1 (en) 2014-12-10
US20130212719A1 (en) 2013-08-15
HUE055610T2 (en) 2021-12-28
NZ627977A (en) 2016-06-24
JP6942757B2 (en) 2021-09-29
LT3597038T (en) 2021-05-25
RS62023B1 (en) 2021-07-30
CN104202971A (en) 2014-12-10
EP2809150B1 (en) 2019-09-18
SG11201404477YA (en) 2014-08-28
CY1124361T1 (en) 2022-07-22
PL3597038T3 (en) 2021-11-08
ES2870703T3 (en) 2021-10-27
IL261280A (en) 2018-10-31
JP6698718B2 (en) 2020-05-27
ME03611B (en) 2020-07-20
JP2023168590A (en) 2023-11-24
PT2809150T (en) 2019-12-09
AU2017251848B2 (en) 2020-02-20
JP2019170395A (en) 2019-10-10
AU2017251848A1 (en) 2017-11-16
BR112014018843B1 (en) 2024-02-20
IL233827A0 (en) 2014-09-30
RU2018122695A (en) 2019-03-06
BR112014018843A8 (en) 2019-01-29
HRP20210987T1 (en) 2021-09-17
JP2023014242A (en) 2023-01-26
WO2013116609A1 (en) 2013-08-08
EP3597038A1 (en) 2020-01-22
CY1122419T1 (en) 2021-01-27
AU2013204758B2 (en) 2015-07-23
ES2753774T3 (en) 2020-04-14
CA2863175A1 (en) 2013-08-08
MX2019002517A (en) 2019-06-17
MX2020003491A (en) 2022-10-25
DK2809150T3 (en) 2019-12-09
KR20140123983A (en) 2014-10-23
IL268675B (en) 2020-11-30
JP2021137030A (en) 2021-09-16
US20210368751A1 (en) 2021-12-02
NZ734504A (en) 2022-10-28
EP3912465A1 (en) 2021-11-24
SI3597038T1 (en) 2021-07-30
JP7187615B2 (en) 2022-12-12
JP2015505477A (en) 2015-02-23
AU2015246154A1 (en) 2015-11-12
AU2015246154B2 (en) 2017-11-23
HK1202771A1 (en) 2015-10-09
PL2809150T3 (en) 2020-04-30
PT3597038T (en) 2021-05-10
LT2809150T (en) 2019-10-25
SG10201606256TA (en) 2016-09-29
RU2770016C2 (en) 2022-04-14
EP3597038B1 (en) 2021-04-21
IL261280B (en) 2019-08-29
DK3597038T3 (en) 2021-06-28
NZ719228A (en) 2022-08-26
AU2013204758A1 (en) 2013-08-15
HUE046744T2 (en) 2020-03-30
RS59699B1 (en) 2020-01-31
KR20190006029A (en) 2019-01-16
CN104202971B (en) 2016-07-06
RU2018122695A3 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
IL268675B (en) Humanized rodents that express heavy chains containing vl domains
IL268674A (en) Humanized il-7 rodents
HK1217958A1 (en) Tetravalent bispecific antibodies
SG11201406726PA (en) Anti-baff-anti-il-17 bispecific antibodies
PT3058134T (en) Extracellular polymers from granular sludge as sizing agents
HK1205145A1 (en) Improved antibody light chains
ZA201306526B (en) Roll-open closure
GB201321568D0 (en) Chain stopper
AU342768S (en) Latch for lunchbox